Dongdong Lu

1.9k total citations
46 papers, 1.6k citations indexed

About

Dongdong Lu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Dongdong Lu has authored 46 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 27 papers in Cancer Research and 8 papers in Oncology. Recurrent topics in Dongdong Lu's work include RNA modifications and cancer (25 papers), Cancer-related molecular mechanisms research (17 papers) and MicroRNA in disease regulation (14 papers). Dongdong Lu is often cited by papers focused on RNA modifications and cancer (25 papers), Cancer-related molecular mechanisms research (17 papers) and MicroRNA in disease regulation (14 papers). Dongdong Lu collaborates with scholars based in China, United States and Canada. Dongdong Lu's co-authors include Qidi Zheng, Tianming Li, Xin Gui, Pu Hu, Mengying Wu, Haiyan Li, Tong Wu, Jiahui An, Chang Han and Xiaoru Xin and has published in prestigious journals such as Gastroenterology, Hepatology and Cancer Cell.

In The Last Decade

Dongdong Lu

46 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dongdong Lu China 22 1.2k 1.0k 192 177 98 46 1.6k
Tae Matsumura Japan 15 1.1k 0.9× 900 0.9× 174 0.9× 290 1.6× 109 1.1× 66 1.6k
Qi-fei Tao China 10 1.8k 1.4× 1.8k 1.7× 233 1.2× 170 1.0× 86 0.9× 17 2.1k
Zhanjun Guo China 21 903 0.7× 433 0.4× 175 0.9× 180 1.0× 95 1.0× 94 1.3k
Lei Deng China 19 1.1k 0.9× 956 0.9× 179 0.9× 242 1.4× 90 0.9× 33 1.5k
Ming-hua Zhu China 21 833 0.7× 461 0.4× 169 0.9× 289 1.6× 110 1.1× 50 1.2k
Shenmeng Gao China 21 894 0.7× 572 0.5× 117 0.6× 154 0.9× 60 0.6× 49 1.2k
Daimin Xiang China 17 1.2k 0.9× 764 0.7× 200 1.0× 301 1.7× 268 2.7× 28 1.6k
Kejun Nan China 24 1.1k 0.9× 829 0.8× 175 0.9× 435 2.5× 148 1.5× 60 1.6k
Yiren Hu China 19 1.0k 0.8× 549 0.5× 98 0.5× 189 1.1× 107 1.1× 45 1.4k

Countries citing papers authored by Dongdong Lu

Since Specialization
Citations

This map shows the geographic impact of Dongdong Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dongdong Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dongdong Lu more than expected).

Fields of papers citing papers by Dongdong Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dongdong Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dongdong Lu. The network helps show where Dongdong Lu may publish in the future.

Co-authorship network of co-authors of Dongdong Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Dongdong Lu. A scholar is included among the top collaborators of Dongdong Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dongdong Lu. Dongdong Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Song, Shuting, et al.. (2023). CircHULC accelerates the growth of human liver cancer stem cells by enhancing chromatin reprogramming and chromosomal instability via autophagy. Cellular Signalling. 109. 110772–110772. 5 indexed citations
2.
Jiang, Xiaoxue, Yi Lü, Yingji Chen, et al.. (2023). miR-624 accelerates the growth of liver cancer cells by inhibiting EMC3. Non-coding RNA Research. 8(4). 641–644. 8 indexed citations
3.
Song, Shuting, et al.. (2023). miR-3200 accelerates the growth of liver cancer cells by enhancing Rab7A. Non-coding RNA Research. 8(4). 675–685. 1 indexed citations
4.
Lu, Yanan, Shujie Li, Shuting Song, et al.. (2022). A lncRNA MEG3 variant enhances telomerase activity by increasing DNA damage repair ability in human liver cancer stem cells. Genes & Diseases. 10(5). 1763–1766. 2 indexed citations
5.
Jiang, Xiaoxue, Shuting Song, Yanan Lu, et al.. (2021). miR-1307 promotes hepatocarcinogenesis by CALR-OSTC-endoplasmic reticulum protein folding pathway. iScience. 24(11). 103271–103271. 8 indexed citations
6.
Yang, Yuxin, Shuting Song, Qiuyu Meng, et al.. (2020). miR24‐2 accelerates progression of liver cancer cells by activating Pim1 through tri‐methylation of Histone H3 on the ninth lysine. Journal of Cellular and Molecular Medicine. 24(5). 2772–2790. 20 indexed citations
7.
Wang, Chen, Xiaoxue Jiang, Xiaonan Li, et al.. (2020). Long noncoding RNA HULC accelerates the growth of human liver cancer stem cells by upregulating CyclinD1 through miR675-PKM2 pathway via autophagy. Stem Cell Research & Therapy. 11(1). 8–8. 35 indexed citations
8.
Jiang, Xiaoxue, Liyan Wang, Yingjie Chen, et al.. (2020). Long noncoding RNA MEG3 blocks telomerase activity in human liver cancer stem cells epigenetically. Stem Cell Research & Therapy. 11(1). 518–518. 21 indexed citations
9.
Xin, Xiaoru, Yanan Lu, Ying‐Jie Chen, et al.. (2020). miR-155 Accelerates the Growth of Human Liver Cancer Cells by Activating CDK2 via Targeting H3F3A. Molecular Therapy — Oncolytics. 17. 471–483. 19 indexed citations
10.
Jiang, Xiaoxue, Libo Xing, Yingjie Chen, et al.. (2020). CircMEG3 inhibits telomerase activity by reducing Cbf5 in human liver cancer stem cells. Molecular Therapy — Nucleic Acids. 23. 310–323. 39 indexed citations
11.
Lu, Yanan, Qiuyu Meng, Chen Wang, et al.. (2018). miR372 Promotes Progression of Liver Cancer Cells by Upregulating erbB-2 through Enhancement of YB-1. Molecular Therapy — Nucleic Acids. 11. 494–507. 21 indexed citations
12.
Zheng, Qidi, Jie Xu, Yanan Lu, et al.. (2018). Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting β-catenin by activating PKM2 and inactivating PTEN. Cell Death and Disease. 9(3). 253–253. 97 indexed citations
13.
Lu, Yanan, Shuting Song, Xiaoxue Jiang, et al.. (2018). miR675 Accelerates Malignant Transformation of Mesenchymal Stem Cells by Blocking DNA Mismatch Repair. Molecular Therapy — Nucleic Acids. 14. 171–183. 7 indexed citations
14.
Zheng, Qidi, Xiaonan Li, Xiaoru Xin, et al.. (2016). Inflammatory cytokine IL6 cooperates with CUDR to aggravate hepatocyte-like stem cells malignant transformation through NF-κB signaling. Scientific Reports. 6(1). 36843–36843. 22 indexed citations
15.
Wu, Mengying, Xiaonan Li, Xiaoru Xin, et al.. (2016). HULC cooperates with MALAT1 to aggravate liver cancer stem cells growth through telomere repeat-binding factor 2. Scientific Reports. 6(1). 36045–36045. 65 indexed citations
16.
Gui, Xin, Haiyan Li, Tianming Li, Pu Hu, & Dongdong Lu. (2015). Long Noncoding RNA CUDR Regulates HULC and β-Catenin to Govern Human Liver Stem Cell Malignant Differentiation. Molecular Therapy. 23(12). 1843–1853. 67 indexed citations
17.
Lu, Dongdong, Yinyuan Wu, Yinyin Wang, et al.. (2012). CREPT Accelerates Tumorigenesis by Regulating the Transcription of Cell-Cycle-Related Genes. Cancer Cell. 21(1). 92–104. 75 indexed citations
18.
Lu, Dongdong, Chang Han, & Tong Wu. (2011). Microsomal Prostaglandin E Synthase-1 Inhibits PTEN and Promotes Experimental Cholangiocarcinogenesis and Tumor Progression. Gastroenterology. 140(7). 2084–2094. 23 indexed citations
19.
Fan, Jian, et al.. (2010). Glucose Transporter Protein 1–Targeted RNA Interference Inhibits Growth and Invasion of the Osteosarcoma Cell Line MG63 In Vitro. Cancer Biotherapy and Radiopharmaceuticals. 25(5). 521–527. 18 indexed citations
20.
Lu, Dongdong, Xiran Zhang, & Xiangrong Cao. (2004). Expression of TN4 gene and its role in human hepatocarcinogenesis from Qidong, a liver cancer risk area.. PubMed. 117(3). 440–4. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tae Matsumura Breakdown of academic impact, for papers by Qi-fei Tao Breakdown of academic impact, for papers by Zhanjun Guo Breakdown of academic impact, for papers by Lei Deng Breakdown of academic impact, for papers by Ming-hua Zhu Breakdown of academic impact, for papers by Shenmeng Gao Breakdown of academic impact, for papers by Daimin Xiang Breakdown of academic impact, for papers by Kejun Nan Breakdown of academic impact, for papers by Yiren Hu
Rankless by CCL
2026